EML4 and non-small cell lung carcinoma: A novel F-circEA was later detected in the plasma of 5 patients with EML4-ALK rearrangement, variant 3b [150]: therefore, F-circEA is a potential diagnostic liquid biopsy biomarker in EML4-ALK+ NSCLC setting.